acetylleucyl-leucyl-norleucinal has been researched along with cinanserin in 2 studies
| Studies (acetylleucyl-leucyl-norleucinal) | Trials (acetylleucyl-leucyl-norleucinal) | Recent Studies (post-2010) (acetylleucyl-leucyl-norleucinal) | Studies (cinanserin) | Trials (cinanserin) | Recent Studies (post-2010) (cinanserin) |
|---|---|---|---|---|---|
| 321 | 0 | 53 | 245 | 12 | 46 |
| Protein | Taxonomy | acetylleucyl-leucyl-norleucinal (IC50) | cinanserin (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.002 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 5 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 5 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.002 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.002 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.182 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amin, SA; Banerjee, S; Gayen, S; Ghosh, K; Jha, T | 1 |
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
1 review(s) available for acetylleucyl-leucyl-norleucinal and cinanserin
| Article | Year |
|---|---|
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
Topics: Antiviral Agents; Catalytic Domain; Coronavirus 3C Proteases; Cysteine Proteinase Inhibitors; Drug Discovery; Drug Evaluation, Preclinical; Molecular Docking Simulation; Molecular Structure; Protein Binding; Quantitative Structure-Activity Relationship; SARS-CoV-2 | 2021 |
1 other study(ies) available for acetylleucyl-leucyl-norleucinal and cinanserin
| Article | Year |
|---|---|
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |